

Supplementary data

Supplementary Table 1. Definition of an all-comers trial.

An all-comers trial was defined as one enrolling patients without the major exclusion criteria listed below.

- a Stenting for multiple lesions or vessels (>3 lesions or stents)
- b Low ejection fraction of left ventricular (<30 or 35%)
- c Haemodialysis
- d ST-segment elevation myocardial infarction
- e Non-ST-segment elevation acute coronary syndrome
- f Severely calcified lesion
- g Thrombotic lesion
- h Chronic total occlusion
- i In-stent restenosis
- j Saphenous vein graft
- k Arterial graft
- l Unprotected left main coronary artery
- m Bifurcated lesion with side branch (>2 mm) or requiring two stents
- n Aorto-ostial lesion
- o Long lesion with length over 30 mm

Supplementary Table 2. Search strategy.

		N of publications
PubMed		
#1	"Coronary Artery Disease"[Mesh]	64,648
#2	coronary[TIAB]	401,835
#3	#1 OR #2	412,330
#4	"Stents"[Mesh]	80,154
#5	stent*[TIAB]	103,181
#6	#4 OR #5	118,029
#7	#3 AND #6	34,902
#8	"randomized controlled trial"[Publication Type]	526,106
#9	"randomized controlled trials as topic"[MeSH Terms]	144,239
#10	#8 OR #9	662,528
#11	#7 AND #10	4,499
Embase		
#1	'coronary artery disease'/exp	339,681
#2	coronary	737,700
#3	#1 OR #2	739,876
#4	'stent'/exp	175,261
#5	stent*	212,905
#6	#4 OR #5	215,209
#7	#3 AND #6	40,842
#8	#7 AND ('controlled clinical trial'/de OR 'randomized controlled trial'/de OR 'randomized controlled trial topic'/de)	3,948
Cochrane Library		
#1	MeSH descriptor: [Coronary Artery Disease] explode all trees	6,525
#2	coronary:ti,ab,kw	56,852
#3	#1 or #2	56,852
#4	MeSH descriptor: [Stents] explode all trees	4,232
#5	stent*:ti,ab,kw	15,567
#6	#4 or #5	15,617
#7	#3 and #6	8,533
#8	#7 in Trials	8,509
#9	#8 not pubmed:an	4,204
#10	#9 not embase:an	1,692

DUTCH PEERS	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
HOST--ASSURE	YES	1	Included	Included	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included
BASKET-PROVE II	NO	5	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Excluded	Excluded	Excluded	Excluded	Included	Not reported	Included
PLATINUM PLUS	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
NEXT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
PROMISE	NO	7	Included	Not reported	Excluded	Excluded	Included	Not reported	Included	Excluded	Excluded	Excluded	Not reported	Excluded	Excluded	Not reported	Included
SORT OUT VI	YES	0	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Not reported	Included	Included	Included	Included
BIOSCIENCE	YES	0	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included
CENTURY II	NO	3	Included	Excluded	Excluded	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
EVOLVE II	NO	6	Included	Not reported	Not reported	Excluded	Included	Not reported	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Not Reported	Not reported	Included
BIO-RESORT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
SORT OUT VII	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
BIOFLOW-IV	NO	15	Excluded	Excluded	Excluded	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
BIONICS	NO	7	Excluded	Excluded	Excluded	Excluded	Included	Included	Not reported	Included	Included	Included	Included	Not reported	Excluded	Not reported	Excluded
HARMONEE	NO	10	Included	Excluded	Excluded	Excluded	Included	Included	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Not reported	Excluded
ReCre8	YES	1	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT VIII	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
BIOFLOW V	NO	10	Included	Excluded	Excluded	Excluded	Included	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Not reported	Included
DESSOLVE III	YES	1	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
BIONYX	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT IX	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
TARGET All Comers	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
TALENT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included

All the eligible 49 trials enrolling non-specific population are listed. The included all-comers trials are highlighted in red.

CTO: chronic total occlusion; EF: ejection fraction; ISR: in-stent restenosis; N: number; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction; SVG: saphenous vein graft

Supplementary Table 4. Patient baseline characteristics and medication of the included trials.

Trial name	Device	N of patients	N of lesions	Mean age	Male (%)	Hypertension (%)	Diabetes (%)	Dyslipidaemia (%)	STEMI (%)	NSTE-ACS (%)	Prior MI (%)	Renal insufficiency (%)	N of lesions treated	Beta-blocker (%)	Statin (%)	ACEI/ARB (%)	DAPT at one year (%)
SIRTAX	CYPHER	503	693	62	75.9	60	21.5	60.6	23.3	27.8	28.8		1.4				
	TAXUS Express	509	708	62	78.4	62.3	18.3	57	21.6	30.1	29.7		1.4				
LEADERS	BioMatrix	857	1,257	64.6	75	73.5	26	65.3	15.8	39.1	32.2		1.5				
	CYPHER	850	1,215	64.5	74.6	72.7	22.5	68.2	16.5	39.2	32.6		1.4				
SORT OUT III	Endeavor	1,162	1,619	64.3	73.3	54	15	70	6	37.5	25						
	CYPHER	1,170	1,611	64.3	73.7	51	14	68	8.5	38.1	26						
COMPARE	XIENCE	897	1,286	62.9	69	46.5	17.1	49.8	26.8	33.6	15	3	1.4				70
	TAXUS Liberté	903	1,294	63.6	72.4	49.5	19	49.9	23.5	35.7	18	3	1.4				70
PROTECT	Endeavor	4,357	6,151	62.3	76.7	64.6	26.9	61.8	8.2	17.6	20		1.4				87
	CYPHER	4,352	6,140	62.1	76	63.4	28.4	62.8	8.8	17.1	21		1.39				88
SORT OUT IV	XIENCE/PROMUS	1,390	1,805	64.2	75.9	56.7	14	71.1	8.8	32.9	21.5		1.3				
	CYPHER	1,384	1,779	64	75.2	53.8	14.2	71.1	10.5	32.7	20.6		1.3				
Resolute All Comer	Resolute	1,140	1,661	64.4	76.7	71.1	23.5	63.9	34.5	19.4	28.9		1.46				
	XIENCE	1,152	1,705	64.2	77.2	71.3	23.4	67.7	33.7	18.9	30.4		1.48				
COMPARE II	Nobori	1,795	2,638	63	74.4	54.8	21.8		20.7	37.2	20.3	4.3	1.5				66.6
	XIENCE	912	1,387	62.7	74.3	56.3	21.6		21.6	36.2	18.8	4.4	1.5				65.9
SORT OUT V	Nobori	1,229	1,532	65	74.6	55.5	15.1	57.8	18.3	30.3	17.7		1.25				
	CYPHER	1,239	1,555	65.2	75.1	52.7	15.3	58.9	18.3	31	17.3		1.26				
RESET	XIENCE	1,597	1,967	68.9	77.5	79.5	45.5	74.5	6.5	11.3	29	2.1	1.23	36.8	77.4	61.8	11.1

	CYPHER	1,600	1,960	69.3	76.1	80.6	44.6	75.3	5.2	13.3	31	2.4	1.23	37.7	77.4	60.9	10.4
DUTCH PEERS	Resolute	906	1,205	64	73.4	55.2	18.4	46.1	19.3	39.6	23	4					
	XIENCE	905	1,166	65	72.6	53	17.3	47.5	21.5	36.8	21	3					
HOST-ASSURE	PROMUS	2,503	3,426	63.1	69.8	68.2	31.8	64	11.3	18.1	4.6	2.4		68.3	84.8	65.4	91.1
	Resolute	1,252	1,661	63.5	65.6	68.1	32	65.7	10.9	16.7	3.9	2.9		67.5	85.9	66.2	92.6
PLATINUM PLUS	PROMUS	1,952	3,289	65.7	77.7	68	29.1	63.4	8.7	28.1	21.7		1.6				59.4
	XIENCE	1,028	1,711	66.1	78.4	68.6	27.2	62.2	9.3	27.6	24.3		1.6				61.2
NEXT	Nobori	1,617	1,985	69.1	77	81.4	46.1	78.2	5.1	11.6	28	2.5	1.27				86.7
	XIENCE/PROMUS	1,618	1,947	69.3	77.4	81.8	45.7	78.1	4.4	11.1	28	2.6	1.24				87.5
SORT OUT VI	Resolute	1,502	1,883	65.7	76.2	59.7	17.6	59.3	19.6	31	18.7		1.3				
	BioMatrix	1,497	1,791	65.8	75.8	58.1	18	59.1	16.9	33.9	19.7		1.3				
BIOSCIENCE	Orsiro	1,063	1,594	66.1	77	68.5	24.2	67	19.8	34.4	21		1.5	47.3	53.6	25.9	83.4
	XIENCE	1,056	1,545	65.9	77.3	66.9	21.7	67.8	18.6	33.9	19.3		1.46	45.4	54.2	26.6	82.1
BIO-RESORT	SYNERGY	1,172	1,532	64	72.1	44.4	17.3	36	32.2	37.5	16	3					85.5
	Resolute	1,173	1,580	63.6	72.3	47.2	17.9	38.4	27.8	41.7	21	3					86.3
	Orsiro	1,169	1,551	64.2	73.1	47	18	39.6	31.7	38.3	18	4					85.1
SORT OUT VII	Orsiro	1,261	1,590	66.1	74.9	58.1	18.7	57.6	21.3	30.8	17.4		1.3				
	Nobori	1,264	1,588	64.8	75.2	56.4	18.6	56.7	20.7	32.6	17.8		1.3				
ReCre8	Resolute	744	1,024	65.1	77.6	55.2	20	45.7	22.4	25	21.2						40.1
	Cre8	747	1,087	64.7	75.6	55.2	20.7	43.5	24.2	22.6	18.6						39.4
SORT OUT VIII	SYNERGY	1,385	1,725	66	76.5	56.1	18.1	54			18						
	BioMatrix	1,379	1,670	66	76.6	57.7	19	52.5			17						
DESSOLVE III	MiStent	703	1,037	66.4	70.3	72	26.6	60.8	14.7	44.2	27	7	1.49				

	XIENCE	695	993	66.3	73.8	75	27.1	60	15.7	43	28	7	1.44
SORT OUT IX	BioFreedom	1,572	1,966	66.4	77.5	56.8	16.7	52.8	23.3	32	14.7		1.3
	Orsiro	1,579	1,985	66.1	77.3	53.8	16.6	49.2	25.1	32	15.2		1.3
BIONYX	Resolute Onyx	1,243	1,646	64.1	76.1	51.5	20.9	45.4	22.7	48.1	16.1	6.7	83.9
	Orsiro	1,245	1,593	63.9	76.1	53.2	20.1	46.4	27.2	43.9	15.6	6.7	82.2
TARGET All Comers	FIREHAWK	823	1,221	64.9	78.1	59.9	24	53	8.4	35.4	21.7	5.5	1.5
	XIENCE	830	1,179	65.3	76.4	62.5	23	51.2	8.9	35.4	24.8	7	1.4
TALENT	Supraflex	720	1,046	66	75.8	65.3	21.8	61.8	16.5	43.1	18.9	2.8	1.45
	XIENCE	715	1,030	65	76	66	24.9	60.2	16.4	40.3	17.9	2	1.44

ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker; AHA/ACC: American Heart Association/American College of Cardiology; DAPT: dual antiplatelet therapy; LVEF: left ventricular ejection fraction; N: number; NSTEMI: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction

Supplementary Table 5. Definitions of myocardial infarction in the included trials.

Trial name	Study start year	Definition of spontaneous MI
SIRTAX	2003	Q or CKMB/cTn>2ULN
LEADERS	2006	ECG or (CK>2ULN + CKMB/cTn>1ULN)
SORT OUT III	2006	Clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰
COMPARE	2007	Clinical/ECG + CKMB/cTn>1ULN
PROTECT	2007	ECG or (clinical + CKMB/cTn>1ULN)
SORT OUT IV	2007	Clinical/ECG + cTn>1ULN [Universal definition]
Resolute All Comers	2008	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹
COMPARE II	2009	Clinical/ECG + CKMB/cTn>1ULN
SORT OUT V	2009	Clinical/ECG + cTn>1ULN [Universal definition]
DUTCH PEERS	2010	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
HOST-ASSURE	2010	Clinical/ECG + cTn>1ULN [Universal definition]
PLATINUM PLUS	2010	(Q + CKMB/cTn>1ULN) or (ECG/clinical + CKMB/cTn>2ULN)
RESET	2010	CKMB/cTn>1ULN [ARC]
NEXT	2011	CKMB/cTn>1ULN [ARC]
SORT OUT VI	2011	Clinical/ECG + cTn>1ULN [Universal definition]
BIO-RESORT	2012	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
BIOSCIENCE	2012	Clinical/ECG + cTn>1ULN [Universal definition]
SORT OUT VII	2012	Clinical/ECG + cTn>1ULN [Universal definition]
ReCre8	2014	CKMB/cTn>1ULN [ARC]
SORT OUT VIII	2014	Clinical/ECG + cTn>1ULN [Universal definition]
BIONYX	2015	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
DESSOLVE III	2015	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
SORT OUT IX	2015	Clinical/ECG + cTn>1ULN [Universal definition]
TARGET All Comers	2015	Clinical/ECG + cTn>1ULN [Universal definition]
TALENT	2016	Clinical/ECG + cTn>1ULN [Universal definition]

ARC: Academic Research Consortium; CKMB: creatine kinase myocardial band; Clinical: clinical findings related to myocardial infarction; cTn: cardiac troponin; ECG: ischaemic change in electrocardiograph; MI: myocardial infarction; Q: Q-wave detected on electrocardiograph; SCAI: Society for Cardiovascular Angiography and Interventions; ULN: upper limit of normal

Summary Table for the definition of spontaneous myocardial infarction

	N of trials
2003 -2007	
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	2
ECG or (CK>2ULN + CKMB/cTn>1ULN)	1
Q or CKMB/cTn>2ULN	1
Clinical/ECG + CKMB/cTn>1ULN	1
ECG or (clinical + CKMB/cTn>1ULN)	1
2008 - 2012	
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	5
(clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹	3
CKMB/cTn>1ULN [ARC] ⁷²	2
(Q + CKMB/cTn>1ULN) or (ECG/clinical + CKMB/cTn>2ULN)	1
2013 - 2016	
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	4
(clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹	2
CKMB/cTn>1ULN [ARC] ⁷²	1

ARC: Academic Research Consortium; CKMB: creatine kinase myocardial band; Clinical: clinical findings related to myocardial infarction; cTn: cardiac troponin; ECG: ischaemic change on electrocardiograph; N: number; Q: Q-wave detected on electrocardiograph; SCAI: Society for Cardiovascular Angiography and Interventions; ULN: upper limit of normal

Supplementary Table 6. Definitions of cardiac death and clinically indicated target lesion revascularisation.

Trial name	Definition for cardiac death	Definition for clinically indicated TLR
SIRTAX	Definition not reported	ARC
LEADERS	ARC	ARC
SORT OUT III	ARC	N/A [#]
COMPARE	ARC	ARC
PROTECT	ARC	N/A [#]
SORT OUT IV	ARC	Clinically driven
Resolute All Comer	ARC	ARC
COMPARE II	ARC	ARC
SORT OUT V	ARC	Clinically driven
DUTCH PEERS	ARC	ARC
HOST-ASSURE	ARC	ARC
PLATINUM PLUS	Death due to MI; arrhythmia or conduction disturbance; deaths related to the procedure; stroke prior to hospital discharge; and death of unknown cause	ARC*
RESET	ARC	ARC
NEXT	ARC	ARC
SORT OUT VI	ARC	Clinically driven
BIO-RESORT	ARC	ARC*
BIOSCIENCE	ARC	ARC*
SORT OUT VII	ARC	Clinically driven
ReCre8	ARC	N/A [#]
SORT OUT VIII	ARC	Clinically driven
BIONYX	ARC	ARC
DESSOLVE III	ARC	ARC
SORT OUT IX	ARC	Clinical-driven
TARGET All Comers	Definition not reported	Definition not reported (ischaemia-driven)
TALENT	ARC	ARC

[#] Trial did not report the incidence of clinically indicated TLR. * The ARC definition was applied but quantitative coronary angiography was not performed at an independent angiographic core laboratory.

ARC: Academic Research Consortium; MI: myocardial infarction; TLR: target lesion revascularisation

Supplementary Table 7. Bias assessment of the included trials.

Trial name	RANDOM SEQUENCE GENERATION	ALLOCATION CONCEALMENT	BLINDING OF PARTICIPANTS AND PERSONNEL*	BLINDING OF OUTCOME ASSESSMENT	INCOMPLETE OUTCOME DATA	SELECTIVE REPORTING	OTHER BIAS
SIRTAX	Low	Low	High	Low	Low	Low	Low
LEADERS	Low	Low	High	Low	Low	Low	Low
SORT OUT III	Low	Low	High	Low	Low	Low	Low
COMPARE	Low	Low	High	Low	Low	Low	Low
PROTECT	Low	Low	High	Low	Low	Low	Low
SORT OUT IV	Low	Low	High	Low	Low	Low	Low
Resolute All Comer	Low	Low	High	Low	Low	Low	Low
COMPARE II	Low	Low	High	Low	Low	Low	Low
SORT OUT V	Low	Low	High	Low	Low	Low	Low
RESET	Low	Low	High	Low	Low	Low	Low
DUTCH PEERS	Low	Low	High	Low	Low	Low	Low
HOST-ASSURE	Low	Low	High	Low	Low	Low	Low
PLATINUM PLUS	Low	Low	High	Low	Low	Low	Low
NEXT	Low	Low	High	Low	Low	Low	Low
SORT OUT VI	Low	Low	High	Low	Low	Low	Low
BIOSCIENCE	Low	Low	High	Low	Low	Low	Low
BIO-RESORT	Low	Low	High	Low	Low	Low	Low
SORT OUT VII	Low	Low	High	Low	Low	Low	Low
ReCre8	Low	Low	High	Low	Low	Low	Low
SORT OUT VIII	Low	Low	High	Low	Low	Low	Low
DESSOLVE III	Low	Low	High	Low	Low	Low	Low
BIONYX	Low	Low	High	Low	Low	Low	Low
SORT OUT IX	Low	Low	High	Low	Low	Low	Low
TARGET All Comers	Low	Low	High	Low	Low	Low	Low
TALENT	Low	Low	High	Low	Low	Low	Low

* In all trials, the operator was not blinded while the assessors (clinical events committee, core laboratory, and statistician) were blinded. Awareness of the allocated stent possibly introduces a bias in the operator's procedure (e.g., lesion preparation, post-dilatation, etc.).

Supplementary Table 8. Performance of routine angiographic follow-up in the included trials.

Study name	Device	N of patients	Month at angio FU	N of patients undergoing angio FU	Patients with angio FU (%)	Month at 1Y TLR	1Y TLR (%)	Angio FU performed before 1Y result
SIRTAX	CYPHER	503	8	267	53.1%	12	5.8%	YES
	TAXUS Express	509		273	53.6%		10.2%	
LEADERS	BioMatrix	857	9	168	19.6%	12	5.2%	YES
	CYPHER	850		167	19.6%		5.8%	
SORT OUT III	Endeavor	1,162	No angio FU			12	5.3%	
	CYPHER	1,170					1.4%	
COMPARE	XIENCE	897	No angio FU			12	1.7%	
	TAXUS Liberté	903					4.8%	
PROTECT	Endeavor	4357	No angio FU			12		
	CYPHER	4,352						
SORT OUT IV	XIENCE/PROMUS	1,390	No angio FU			9	1.4%	
	CYPHER	1,384					1.7%	
Resolute All Comer	Resolute	1,140	13	142	12.5%	12	3.9%	NO
	XIENCE	1,152		130	11.3%		3.4%	
COMPARE II	Nobori	1,795	No angio FU			12	2.1%	
	XIENCE	912					1.8%	
SORT OUT V	Nobori	1,229	No angio FU			12	3.3%	
	CYPHER	1,239					2.0%	
DUTCH PEERS	Resolute	906	No angio FU			12	2.2%	
	XIENCE	905					2.2%	
HOST-ASSURE	PROMUS	2,503	No angio FU			12	1.3%	
	Resolute	1,252					1.2%	
PLATINUM PLUS	PROMUS Element	1,952	No angio FU			12	2.0%	
	XIENCE	1,028					1.6%	
RESET	XIENCE	1,597	8	235	14.7%	12	2.9%	YES
	CYPHER	1,600		247	15.4%		3.7%	
NEXT	Nobori	1,617	8	227	14.0%	12	2.9%	YES
	XIENCE/PROMUS	1,618		230	14.2%		2.9%	
SORT OUT VI	Resolute	1,502	No angio FU			12	3.5%	
	BioMatrix	1,497					3.1%	
BIO-RESORT	SYNERGY	1,172	No angio FU			12	1.5%	
	Resolute	1,173					1.5%	
	Orsiro	1,169					1.5%	
BIOSCIENCE	Orsiro	1,063	No angio FU			12	3.4%	
	XIENCE	1,056					2.4%	
SORT OUT VII	Orsiro	1,261	No angio FU			12	2.0%	
	Nobori	1,264					2.9%	
ReCre8	Resolute	751	No angio FU			12		
	Cre8	751						
SORT OUT VIII	SYNERGY	1,385	No angio FU			12	2.3%	
	BioMatrix	1,379					2.5%	
BIONYX	Resolute Onyx	1,243	No angio FU			12	2.5%	
	Orsiro	1,245					2.0%	

DESSOLVE III	MiStent	703	No angio FU			12	2.6%	
	XIENCE	695					3.7%	
SORT OUT IX	BioFreedom	1,572	No angio FU			12	3.5%	
	Orsiro	1,579					1.3%	
TARGET All Comers	FIREHAWK	823	13	71	8.6%	12	1.1%	NO
	XIENCE	830		66	8.0%		2.3%	
TALENT	Supraflex	720	No angio FU			12	2.7%	
	XIENCE	715					4.0%	

angio: angiography; FU: follow-up; N: number; TLR: target lesion revascularisation; Y: year


Supplementary Table 9. List of antiplatelet therapy regimens and bleeding event rates in the included trials.

Study name	Study start year	Device	N of patients	Recommended DAPT duration (months)	Recommended P2Y ₁₂ inhibitor	Percent of patients on DAPT at 1 year	Percent of patients with major bleeding at 1 year	Definition for bleeding event
SIRTAX	2003	CYPHER	503	12	Clopidogrel	Not reported	Not reported	NA
		TAXUS Express	509			Not reported	Not reported	NA
LEADERS	2006	BioMatrix	857	12	Clopidogrel	Not reported	Not reported	NA
		CYPHER	850			Not reported	Not reported	NA
SORT OUT III	2006	Endavor	1,162	12	Clopidogrel	Not reported	Not reported	NA
		CYPHER	1,170			Not reported	Not reported	NA
COMPARE	2007	XIENCE	897	12	Clopidogrel	70.0	Not reported	NA
		TAXUS Liberté	903			70.0	Not reported	NA
PROTECT	2007	Endavor	4,357	3 to 12	Ticlopidine or clopidogrel	87.0	Not reported (only 2-year incidence reported)	TIMI
		CYPHER	4,352			88.0	Not reported (only 2-year incidence reported)	TIMI
SORT OUT IV	2007	XIENCE / PROMUS	1,390	12	Clopidogrel or prasugrel	Not reported	Not reported	NA
		CYPHER	1,384			Not reported	Not reported	NA
Resolute All Comer	2008	Resolute	1,140	At least 6	Clopidogrel	Not reported	Not reported	NA
		XIENCE	1,152			Not reported	Not reported	NA
COMPARE II	2009	Nobori	1,795	12	Clopidogrel	67.0	Not reported	NA
		XIENCE	912			66.6	Not reported	NA
SORT OUT V	2009	Nobori	1,229	12	Clopidogrel or prasugrel	Not reported	Not reported	NA
		CYPHER	1,239			Not reported	Not reported	NA
DUTCH PEERS	2010	Resolute	906	12	Clopidogrel	Not reported	Not reported	NA
		XIENCE	905			Not reported	Not reported	NA
HOST-ASSURE	2010	PROMUS	2,503	Not reported	Double dose of clopidogrel or normal dose of clopidogrel plus cilostazol	91.1	1.1	PLATO
		Resolute	1,252			92.6	1.3	PLATO
PLATINUM PLUS	2010	PROMUS Element	1,952	At least 6	Clopidogrel or prasugrel	59.4	Not reported	NA
		XIENCE	1,028			61.2	Not reported	NA
RESET	2010	XIENCE	1,597	At least 3	Ticlopidine or clopidogrel	89.0	1.0	TIMI
		CYPHER	1,600			90.0	1.3	TIMI
NEXT	2011	Nobori	1,617	At least 3	Ticlopidine or clopidogrel	86.7	1.1	TIMI
		XIENCE / PROMUS	1,618			87.5	0.9	TIMI
SORT OUT VI	2011	Resolute	1,502	12	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		BioMatrix	1,497			Not reported	Not reported	NA
BIO-RESORT	2012	SYNERGY	1,172	6 to 12	Clopidogrel, ticagrelor or prasugrel	85.5	Not reported	NA
		Resolute	1,173			86.3	Not reported	NA
		Orsiro	1,169			85.1	Not reported	NA
BIOSCIENCE	2012	Orsiro	1,063	12	Clopidogrel, ticagrelor or prasugrel	83.4	2.9	BARC 3-5
		XIENCE	1,056			82.1	2.6	BARC3-5
SORT OUT VII	2012	Orsiro	1,261	12	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA

		Nobori	1,264			Not reported	Not reported	NA
ReCre8	2014	Resolute	751	1 for Tn negative / 12 Tn positive	Clopidogrel, ticagrelor or prasugrel	40.1	1.7	BARC 3-5
		Cre8	751			39.4	1.6	BARC 3-5
SORT OUT VIII	2014	SYNER Y	1,385	12	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		BioMatri x	1,379			Not reported	Not reported	NA
BIONYX	2015	Resolute Onyx	1,243	At least 6 for stable coronary disease / 12 for ACS	Clopidogrel, ticagrelor or prasugrel	83.9	2.5	BARC 3 or 5 or any TIMI
		Orsiro	1,245			82.2	2.7	BARC 3 or 5 or any TIMI
DESSOLVE III	2015	MiStent	703	At least 6	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		XIENCE	695			Not reported	Not reported	NA
SORT OUT IX	2015	BioFree dm	1,572	6 for stable coronary disease / 12 for ACS	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		Orsiro	1,579			Not reported	Not reported	NA
TARGET All Comers	2015	FIREHA WK	823	At least 6 for stable coronary disease / 12 for ACS	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		XIENCE	830			Not reported	Not reported	NA
TALENT	2016	Suprafle x	720	At least 6 for stable coronary disease / 12 for ACS	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA
		XIENCE	715			Not reported	Not reported	NA


ACS: acute coronary syndrome; DAPT: dual antiplatelet therapy; N: number; NA: not applicable; TIMI: Thrombolysis In Myocardial Infarction; Tn: troponin

BioFreedom™ (Biosensors, Singapore)
BioMatrix™ (Biosensors, Singapore)
Cre8™ (Alvimedica, Istanbul, Turkey)
CYPHER® (Cordis Santa Clara, CA, USA)
Endeavor® (Medtronic, Minneapolis, MN, USA)
FIREHAWK® (MicroPort, Shanghai, China)
MiStent® (Micell Technologies, Durham, NC, USA)
Nobori® (Terumo Corp., Tokyo, Japan)
Orsiro (Biotronik, Berlin Germany)
PROMUST™ (Boston Scientific, Marlborough, MA, USA)
Resolute™ (Medtronic, Minneapolis, MN, USA)
Resolute Onyx™ (Medtronic, Minneapolis, MN, USA)
Supraflex™ (Sahajanand Medical Technologies, Mumbai, India)
SYNERGY™ (Boston Scientific, Marlborough, MA, USA)
TAXUS Express (Boston Scientific, Marlborough, MA, USA)
TAXUS™ Liberté™ (Boston Scientific, Marlborough, MA, USA)
XIENCE® (Abbott Laboratories, Abbott Park, IL, USA)




Supplementary Figure 1. Study selection process.

N: number; RCT: randomised controlled trial




Study start year	N of study arms	N of patients	Incidence (%) [95%CI]
2003-2007	10	9600	1.63 [1.27, 1.99]
2008-2012	19	23135	1.27 [1.09, 1.45]
2013-2016	12	11787	1.14 [0.86, 1.41]
Total			1.32 [1.17, 1.47]

$\chi^2 = 874.58, df = 63, p < 0.001, I^2 = 99.8\%$




Study start year	N of study arms	N of patients	Incidence (%) [95%CI]
2003-2007	6	4495	3.74 [2.58, 4.90]
2008-2012	11	13339	2.94 [2.21, 3.66]
2013-2016	8	5872	3.55 [2.83, 4.26]
Total			3.32 [2.84, 3.81]

$\chi^2 = 1386.42, df = 34, p < 0.001, I^2 = 99.9\%$




Study start year	N of study arms	N of patients	Incidence (%) [95%CI]
2003-2007	10	9600	4.32 [2.57, 6.08]
2008-2012	19	23135	2.43 [2.08, 2.79]
2013-2016	10	10296	2.60 [2.01, 3.19]
Total			2.96 [2.41, 3.51]

$\chi^2 = 2187.10, df = 38, p < 0.001, I^2 = 99.9\%$



Study start year	N of study arms	N of patients	Incidence (%) [95%CI]
2003-2007	10	9600	1.23 [0.75, 1.71]
2008-2012	19	23135	0.53 [0.39, 0.67]
2013-2016	12	11787	0.78 [0.66, 0.90]
Total			0.77 [0.61, 0.93]

$Q = 10206.90$, $df = 43$, $p = 0.00$, $I^2 = 99.9\%$



Study start year	N of study arms	N of patients	Incidence (%) [95%CI]
2003-2007	10	9511	2.80 [1.89, 3.72]
2008-2012	10	11185	1.36 [1.14, 1.58]
Total			2.08 [1.52, 2.64]

$Q = 11814.05$, $df = 19$, $p = 0.00$, $I^2 = 99.9\%$

Supplementary Figure 2. The results of sensitivity analysis.

